Hemostemix Inc. (CVE:HEM – Get Free Report) traded down 11.1% on Monday . The company traded as low as C$0.15 and last traded at C$0.16. 16,232,833 shares changed hands during mid-day trading, an increase of 1,789% from the average session volume of 859,337 shares. The stock had previously closed at C$0.18.
Hemostemix Trading Down 13.9 %
The firm has a market capitalization of C$22.59 million, a PE ratio of -4.52 and a beta of 0.20. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The company has a fifty day moving average of C$0.21 and a 200-day moving average of C$0.12.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- What is an Earnings Surprise?
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- How to Use Stock Screeners to Find Stocks
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- Top Stocks Investing in 5G Technology
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
